ArticleThe journal of obstetrics and gynaecology research2025
The effect of dolutegravir on obstetrical outcomes among women living with HIV: A retrospective cohort study.
Article in The journal of obstetrics and gynaecology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Inflammation at the maternal-fetal interface: a perspective on interacting risk factors for preterm birth in sub-Saharan African women living with HIV.Frontiers in immunology · 2026Review
- The effect of dolutegravir on obstetrical outcomes among women living with HIV: A retrospective cohort study.The journal of obstetrics and gynaecology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the effect of dolutegravir (DTG) on obstetrical outcomes for women living with HIV (WLWH).
methodsThis retrospective cohort study evaluated adult WLWH in antenatal care between 2016 and 2022 at two Nigerian centers. Patients were stratified into three antiretroviral therapy (ART) exposure groups: non-DTG ART, DTG-switch, and DTG. Multivariate linear and logistic regression models were utilized to assess the association between the type of ART and gestational weight gain (GWG), small for gestational age (SGA), gestational hypertension, and preterm birth.
resultsThe study included 1839 (77.1%) non-DTG users, 359 (15%) DTG users, and 188 (7.9%) DTG switchers. The adjusted association between DTG exposure and GWG was 0.72 (-0.08, 1.53) kg and 0.51 (-0.51, 1.54) kg for the DTG and DTG-switch groups, respectively, compared to other ARTs. The adjusted odds ratios for gestational hypertension were 0.47 (0.09, 2.49) and 1.31 (0.43, 4.02), 0.57 (0.22, 1.52) and 0.73 (0.25, 2.10) for preterm birth, and 0.55 (0.25, 1.20) and 0.26 (0.08, 0.83) for SGA in DTG and DTG-switch, respectively, compared to other ARTs.
conclusionsDTG therapy is not associated with the risk of gestational hypertension nor preterm birth, and antenatal ART switching to DTG decreases the risk of growth restriction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.